Moody National Bank Trust Division’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $439K | Buy |
+2,313
| New | +$435K | 0.04% | 364 |
|
|
2026
Q1 | – | Sell |
-2,713
| Closed | -$499K | – | 505 |
|
|
2025
Q4 | $499K | Buy |
2,713
+33
| +1% | +$5.79K | 0.05% | 341 |
|
|
2025
Q3 | $411K | Sell |
2,680
-39
| -1% | -$5.9K | 0.03% | 370 |
|
|
2025
Q2 | $380K | Sell |
2,719
-225
| -8% | -$31.5K | 0.03% | 373 |
|
|
2025
Q1 | $433K | Buy |
2,944
+666
| +29% | +$96.4K | 0.05% | 359 |
|
|
2024
Q4 | $299K | Buy |
2,278
+379
| +20% | +$53.1K | 0.03% | 401 |
|
|
2024
Q3 | $296K | Buy |
+1,899
| New | +$307K | 0.03% | 395 |
|
|
2024
Q1 | – | Sell |
-1,627
| Closed | -$219K | – | 464 |
|
|
2023
Q4 | $219K | Hold |
1,627
| – | – | 0.02% | 445 |
|
|
2023
Q3 | $220K | Sell |
1,627
-175
| -10% | -$23.9K | 0.01% | 556 |
|
|
2023
Q2 | $258K | Hold |
1,802
| – | – | 0.02% | 550 |
|
|
2023
Q1 | $250K | Buy |
1,802
+258
| +17% | +$34.7K | 0.02% | 547 |
|
|
2022
Q4 | $210K | Sell |
1,544
-898
| -37% | -$113K | 0.02% | 571 |
|
|
2022
Q3 | $268K | Buy |
2,442
+485
| +25% | +$61.5K | 0.03% | 501 |
|
|
2022
Q2 | $259K | Sell |
1,957
-1,531
| -44% | -$201K | 0.03% | 445 |
|
|
2022
Q1 | $463K | Hold |
3,488
| – | – | 0.01% | 287 |
|
|
2021
Q4 | $406K | Sell |
3,488
-10,913
| -76% | -$1.28M | 0.01% | 295 |
|
|
2021
Q3 | $1.73M | Buy |
14,401
+627
| +5% | +$73K | 0.03% | 244 |
|
|
2021
Q2 | $1.65M | Sell |
13,774
-55
| -0.4% | -$6.03K | 0.03% | 250 |
|
|
2021
Q1 | $1.38M | Buy |
13,829
+100
| +0.7% | +$10.1K | 0.03% | 260 |
|
|
2020
Q4 | $1.37M | Sell |
13,729
-314
| -2% | -$33.3K | 0.04% | 240 |
|
|
2020
Q3 | $1.54M | Sell |
14,043
-201
| -1% | -$22.4K | 0.05% | 217 |
|
|
2020
Q2 | $1.51M | Buy |
14,244
+38
| +0.3% | +$3.92K | 0.05% | 214 |
|
|
2020
Q1 | $1.27M | Buy |
14,206
+35
| +0.2% | +$3.29K | 0.04% | 210 |
|
|
2019
Q4 | $1.41M | Buy |
14,171
+52
| +0.4% | +$4.9K | 0.04% | 215 |
|
|
2019
Q3 | $1.26M | Buy |
14,119
+157
| +1% | +$13.6K | 0.04% | 224 |
|
|
2019
Q2 | $1.15M | Sell |
13,962
-221
| -2% | -$17.3K | 0.03% | 226 |
|
|
2019
Q1 | $1.15M | Sell |
14,183
-7
| -0% | -$552 | 0.03% | 227 |
|
|
2018
Q4 | $1.08M | Buy |
14,190
+1,615
| +13% | +$126K | 0.03% | 224 |
|
|
2018
Q3 | $995K | Buy |
+12,575
| New | +$951K | 0.03% | 235 |
|
|
2014
Q4 | – | Sell |
-7,650
| Closed | -$546K | – | 261 |
|
|
2014
Q3 | $546K | Buy |
7,650
+3,000
| +65% | +$220K | 0.04% | 147 |
|
|
2014
Q2 | $345K | Buy |
+4,650
| New | +$336K | 0.02% | 214 |
|
|
2013
Q4 | – | Sell |
-7,000
| Closed | -$364K | – | 247 |
|
|
2013
Q3 | $364K | Hold |
7,000
| – | – | 0.03% | 181 |
|
|
2013
Q2 | $331K | Buy |
+7,000
| New | +$356K | 0.03% | 183 |
|
Other funds holding AZN
RG
SAM
CDDEC
MGP
Moody National Bank Trust Division's AZN Position: Q2 2026 in Review
Moody National Bank Trust Division opened a new position in AstraZeneca (AZN) in Q2 2026: 2,313 shares worth $439K. The stake represents 0.04% of the portfolio and ranks #364 among its holdings. This is a return to the name: Moody National Bank Trust Division previously reported a position in AZN as recently as Q4 2025.
Moody National Bank Trust Division first reported a position in AZN in Q2 2013 and has held it in 33 quarters since. The position peaked at $1.73M in Q3 2021. 853 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Moody National Bank Trust Division held 2,313 shares of AstraZeneca worth $439K as of Q2 2026.
- AstraZeneca was a new Moody National Bank Trust Division position in Q2 2026.
- AstraZeneca made up 0.04% of Moody National Bank Trust Division's portfolio in Q2 2026, its #364 holding.
- Moody National Bank Trust Division first reported a position in AstraZeneca in Q2 2013 and has held it in 33 quarters since.
- Moody National Bank Trust Division's AstraZeneca position peaked at $1.73M in Q3 2021.
- 853 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Moody National Bank Trust Division's 13F filing for Q2 2026, filed 7 Jul 2026.